Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CD70 CAR-T by UTC Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval
CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma. According...
Data Insights
CD70 CAR-T by UTC Therapeutics for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL)....